FDA Panels Debate Pricing, Promotions For Plan B OTC
This article was originally published in The Tan Sheet
Executive Summary
Barr Laboratories' efforts to increase access to its emergency contraceptive Plan B should include measures to make the drug accessible to women who cannot afford the morning-after pill, some panelists said at a joint meeting of the Nonprescription Drugs and Reproductive Health Drugs advisory committees in Gaithersburg, Md. Dec. 16
You may also be interested in...
Barr, FDA Will Meet On Plan B Switch; Agency Says Rulemaking Not Needed
The approval process for the over-the-counter sale of Barr's emergency contraceptive Plan B could be "wrapped up in a matter of weeks if [Barr and FDA] work diligently" together, according to an FDA spokesperson
Barr, FDA Will Meet On Plan B Switch; Agency Says Rulemaking Not Needed
The approval process for the over-the-counter sale of Barr's emergency contraceptive Plan B could be "wrapped up in a matter of weeks if [Barr and FDA] work diligently" together, according to an FDA spokesperson
Barr, FDA Will Meet On Plan B Switch; Agency Says Rulemaking Not Needed
The approval process for the over-the-counter sale of Barr's emergency contraceptive Plan B could be "wrapped up in a matter of weeks if [Barr and FDA] work diligently" together, according to an FDA spokesperson